Business Context and Reporting Period
Company: Emerald Medical Applications Corp. (Note: Input metadata referenced "Quantum X Labs Inc.", but the filing text identifies the registrant as Emerald Medical Applications Corp.)
Reporting Period: Quarterly period ended June 30, 2017 (Form 10-Q).
Business Overview: A digital health startup developing "DermaCompare," a proprietary software for derma imaging and analytics to assist in skin cancer screening. The company is in the development stage with no commercial revenue to date.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2017 | Six Months Ended June 30, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,694,608) | $(3,088,204) |
| Operating Expenses | $1,032,427 | $3,115,751 |
| Finance Expense | $(662,181) | $27,547 (Income) |
| Cash and Cash Equivalents (End of Period) | $14,110 | $274,562 |
| Total Current Liabilities | $2,042,931 | $958,197 |
| Working Capital | $(2,025,163) | $(944,355) |
Liquidity: The company reported negative working capital of approximately $2.0 million. Cash flow from operations was negative $511,652, while financing activities provided $526,231 primarily from the sale of common stock.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $1.4 million compared to the prior year period, primarily due to a significant reduction in General and Administrative (G&A) expenses.
- G&A Expenses: Dropped from $2.82 million (6 months 2016) to $682,606 (6 months 2017). The prior year included significant merger-related costs and share-based compensation not present in the current period.
- Finance Costs: Finance income of $27,547 in the prior year turned into an expense of $662,181. This increase is attributed to penalties and liquidation damages recorded under a settlement agreement with convertible note holders (Alpha Anstalt Capital and Chi Squared Capital Inc.).
- Liabilities: Total current liabilities more than doubled, driven by a new provision of $740,860 for the settlement of convertible notes and an increase in the principal amount of convertible notes.
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes an explanatory paragraph regarding "going concern." The company has limited capital and requires additional financing (estimated at $1.5 million) to continue operations for the next 12 months.
- Debt Settlement: In August 2017 (subsequent event), the company settled disputes with note holders by extending maturity dates to 2019 but increasing principal amounts and issuing Series A Convertible Preferred Stock. This resulted in a $740,860 provision recorded in the current period.
- Revenue Outlook: The company has generated no revenue. Future plans involve selling software licenses to healthcare providers, but commercialization is not yet achieved.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2017.
- Risks: Risks include the inability to raise additional capital, dependence on successful R&D outcomes, and potential expiration of net operating losses before utilization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $14,110 cash balance against the stated need for $1.5 million in additional capital.
- Debt Obligations: Confirm the terms of the August 2017 settlement agreement regarding the increased principal on convertible notes and the issuance of Series A Preferred Stock.
- Revenue Generation: Assess the timeline for commercializing the DermaCompare software and securing paying customers.
- Internal Controls: Review the specific material weaknesses identified in the ineffective disclosure controls.
- Related Party Transactions: Verify the $88,178 outstanding payable to related parties and the nature of services provided.